News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Startup Genome described Philly as "a vibrant Life Science hub and a particularly attractive home base for female entrepreneurs."
The Penn community gathered on College Green to welcome the new president.
In a proof-of-concept study, a robotic microswarm of nanoparticles, arranged in bristle-like structures, effectively cleaned plaque and decay-causing bacteria from both mock and human teeth.
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
PCIV startup Peroxitech Inc. announced the successful completion of a $25M Series A financing for treatment of acute lung injury (ALI) into clinical development.
Mike Mitchell's lab has numerous ongoing research partnerships to support new therapeutic solutions with commercial entities that were facilitated by PCI.
As the number of gene and cell therapy jobs continue to grow, Philadelphia continues to attract diverse pools of talent.
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.
Read about the current state of the biopharma industry in the face of pending patent cliff.
Penn and Carisma Therapeutics (Carisma) have strengthened the intellectual property portfolio covering this technology with the issuance of five additional patents in 2022.